Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 7/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321602 | 1.00 | ACE (0.58) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL8216927 | 1.00 | ACE (0.58) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL6253538 | 0.91 | ACE (0.49) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL2633846 | 0.89 | ACE (0.47) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL7070376 | 0.85 | TGFBR1 (0.52) | ACEFOLH1OR51E2MMETGFBR1 | |
| SCHEMBL6009831 | 0.85 | TGFBR1 (0.52) | ACEFOLH1OR51E2MMETGFBR1 | |
| SCHEMBL8491732 | 0.80 | OR51E2 (0.44) | ACEFOLH1OR51E2MMETGFBR1 | |
| SCHEMBL29837094 | 0.80 | OR51E2 (0.44) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL28806122 | 0.80 | OR51E2 (0.44) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL8491734 | 0.80 | OR51E2 (0.44) | ACEFOLH1OR51E2MMETGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515476-B1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTIEPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | AMAL THERAPEUTICS SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-3429618-B1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3693009-B1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-4228681-A1 | COMBINATION OF A STING AGONIST AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST | Boehringer Ingelheim International GmbH (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4210734-A1 | HETEROLOGOUS PRIME BOOST VACCINE | Boehringer Ingelheim International GmbH (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20230035037-A1 | TEIPP PEPTIDE VARIANT AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2023-02-02 | — | — | US | disclosed |
| US-20220175933-A1 | Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma | AMAL THERAPEUTICS SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11338027-B2 | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer | AMAL THERAPEUTICS SA (CH) | 2022-05-24 | — | — | US | disclosed |
| WO-2022079175-A1 | COMBINATION OF A STING AGONIST AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
| US-20220118102-A1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2022-04-21 | — | — | US | disclosed |
| EP-2732825-B1 | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist | INVIVOGEN (FR) | 2015-07-01 | — | — | EP | disclosed |
| US-20140242108-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | CAYLA (FR) | 2014-08-28 | — | — | US | disclosed |
| EP-2769738-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | Invivogen (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20140141033-A1 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS | CAYLA (FR) | 2014-05-22 | — | — | US | disclosed |
| EP-2732825-A1 | Conjugated TLR7 and/or TLR8 and TLR2 agonists | Invivogen (FR) | 2014-05-21 | — | — | EP | disclosed |
| WO-2009137103-A2 | ANTI-CANCER/ANTI-VIRAL COMPOUNDS AND METHODS OF USE | OURTH DONALD D (US) | 2009-11-12 | — | — | WO | disclosed |
| US-6074650-A | INDUCTION OF CYTOTOXIC LYMPHOCYTES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | disclosed |
| US-6024964-A | ANTIBODIES AND ANTIGENS WITH MEMBRANE ANCHORING | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |
| EP-0210412-B1 | Anchoring membrane ingredient conjugate, and its use | HOECHST AG (DE) | 1995-12-13 | — | — | EP | disclosed |
| EP-0210412-A2 | Anchoring membrane ingredient conjugate, and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141033-A1 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS | TLR7, TLR8, TLR9 | ACE 4600/4885KDM4E 1468/4885MAPT 3375/4885 |
| US-20140242108-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | TLR7, TLR8, TLR9 | ACE 4793/4885KDM4E 1683/4885MAPT 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.